SLC5A2 and type 2 diabetes mellitus: As a target, SGLT2 inhibitors act on the proximal tubules of the kidneys and have efficacy in the management of T2D and cardiovascular and renal safety (Park et al., 2007; Fioretto et al., 2016; Cowie et al., 2020; DeFronzo et al., 2021).